Abstracts tagged "meta-analysis and psoriatic arthritis"

Abstract Number: 696 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis
Chenyang Lu^1,2, Beth Wallace^3,4,5, Wenyi Fu^2,6 and Yi Liu¹, ¹Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, China, ²Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ³VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, ⁴Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ⁵Institute for Healthcare Policy and Innovation, Michigan Medicine, Ann Arbor, MI, ⁶Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China, Shenyang, China
Background/Purpose: Many targeted synthetic DMARD (tsDMARD) and biological DMARD (bDMARD) were recently approved for treatment of active psoriatic arthritis (PsA), but their comparative efficacy and…
Abstract Number: 701 • 2018 ACR/ARHP Annual Meeting
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment
Vibeke Strand¹, M. Elaine Husni², Jenny Griffith³, Yan Song⁴, Rakesh Singh⁵, Jing Zhao⁶ and Keith A. Betts⁷, ¹Stanford University, Palo Alto, CA, ²Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ³AbbVie, Inc., North Chicago, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Analysis Group Inc, Boston, MA, ⁷Analysis Group, Inc., Los Angeles, CA
Background/Purpose: With multiple targeted immunomodulators (TIMs) approved by the FDA for the treatment of psoriatic arthritis (PsA), the relative efficacy and cost-effectiveness of these TIMs…
Abstract Number: 1651 • 2018 ACR/ARHP Annual Meeting
Epidemiology of Depression and Anxiety in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis
Enav Z. Zusman^1,2,3, Alyssa Howren^1,2,3, Jan Dutz⁴ and Mary A. De Vera^1,2,3, ¹Collaboration for Outcomes Research and Evaluation (CORE), Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Shared inflammatory processes underscore a substantial burden and risk of psychiatric complications – namely depression and anxiety – in patients with psoriatic arthritis (PsA),…
Abstract Number: 2564 • 2018 ACR/ARHP Annual Meeting
Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients
Alice B Gottlieb¹, Philip J. Mease², Bruce Kirkham³, Peter Nash⁴, Alejandro Balsa⁵, Bernard Combe⁶, Juergen Rech⁷, Ruvie Martin⁸, Gregory Ligozio⁸, Ken Abrams⁸ and Luminita Pricop⁹, ¹Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴University of Queensland, Brisbane, Australia, ⁵Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, ⁶Rheumatology, CHU Montpellier, Montpellier University, Montpellier, France, ⁷Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab provided rapid, significant and sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) in multiple Phase 3 studies.1-4 Herein, we report…
Abstract Number: 635 • 2017 ACR/ARHP Annual Meeting
Short-Term Efficacy and Safety of New Biological Agents Targeting the IL-6, IL-12/23 and IL-17 Pathways for Active Psoriatic Arthritis: A Network Meta-Analysis of Randomised Controlled Trials
Dongze Wu, Jiang Yue and Lai-Shan Tam, Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: According to EULAR recommendations, in patients with peripheral arthritis and an inadequate response to at least one conventional synthetic DMARD, biologic DMARDs targeting IL-12/23,…
Abstract Number: 1562 • 2017 ACR/ARHP Annual Meeting
Biological DMARD Efficacy in Psoriatic Arthritis: A Systematic Review and Meta-Analysis on ACR Response Criteria, PASI Response Criteria, HAQ-DI, Enthesitis and Dactylitis Outcomes
Numa Simons¹, Yannick Degboé¹, Thomas Barnetche², Alain Cantagrel¹, Adeline Ruyssen-Witrand¹ and Arnaud Constantin¹, ¹Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ²FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France
Background/Purpose: We are currently witnessing a diversification of the available biotherapies (bDMARDs) for psoriatic arthritis (PsA), with the arrival of new classes of medication. Those…
Abstract Number: 2848 • 2015 ACR/ARHP Annual Meeting
Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Vibeke Strand¹, M. Elaine Husni², William Reichmann³, Keith Betts⁴, Jenny Griffith⁵, Yan Song³, Marci Beppu⁶ and Arijit Ganguli⁵, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group Inc., Boston, MA, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie, Newcastle, WA
Background/Purpose: Multiple disease-modifying therapies for treatment of psoriatic arthritis (PsA) are available. However, there are limited data directly comparing these biologic therapies and the recently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].